Participate in a T1D Clinical Trial in Northern California

Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing and treating T1D. There are many opportunities in the Northern California area to participate in a T1D clinical trial close to home. You can check out local and virtual clinical trials presently recruiting in the section below. Additionally, Breakthrough T1D has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting breakthrought1d.org/impact/research/clinical-trials today!

Quick Flyer Links:

Currently Recruiting Disease-Modifying Therapy Clinical Trials

Currently Recruiting Cell Therapy Clinical Trials

Currently Recruiting Virtual Clinical Trials

If you have any questions, please contact Jennifer Pliner, Breakthrough T1D Outreach Coordinator for Northern California, at JPliner@BreakthroughT1D.org.

FEATURED T1D STUDIES IN NORTHERN CALIFORNIA

VIRTUAL

Researchers at UCSF are participating in the Commercial or Open Source Closed Loop Impact on Pregnancy (COSCLIP) Study. COSCLIP is a nationwide study of pregnant people with type 1 diabetes who use automated insulin delivery (AID) systems for diabetes management in pregnancy. Participants will be asked to remotely share their AID system data with the research team and complete online surveys regarding behavioral and emotional health.

• Contact: clipstudy@ucsf.edu

Researchers at Stanford are conducting The Diabetes Wellness Teen Study, investigating risk factors that predict the future onset of body image and eating behavior concerns in adolescents with type 1 diabetes. Female-identifying individuals who have type 1 diabetes and are using a continuous glucose monitor are invited to participate. Participants can earn up to $125 over the course of the study!

• Age: 11-17
• Contact:  shirazh@stanford.edu

Researchers at UCSF are trying to optimize diabetes technology use for Latinx youth through DREAM (Device Use Reimagined Through Education And Mentorship). Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control, which reduces risk for diabetes complications. Many Latinx adolescents use these devices less often. This study evaluates Virtual Peer Groups are being evaluated. Participants may experience benefits from peer support and education, with compensation of up to $125 .

• Age: 13-17 years old + caregivers
• Receiving diabetes care at UCSF, CHLA or UC Davis
• Self-identify as Latina/o/x or other variations such as Hispanic
• Contact: cristina.acostanavarro@ucsf.edu

Researchers at Stanford are conducting the BEAD-T1D study, which aims to increase the use of diabetes technology among disadvantaged youths. The study explores barriers to care, and aims to improve diabetes management and outcomes in this group.

• Age: 12-21
• Contact: aaddala@stanford.edu

Stanford University’s Time in Tight Range Study is recruiting participants 18 and older to complete an anonymous survey about their views on a new metric to assess diabetes outcomes.

• Ag: 18+
• Contact: Molly Tanenbaum at titrstudy@standford.edu

University of California, San Francisco is running a virtual study Extended Bolus for Meals in a Closed-Loop System for participants ages 13-18 who use Control IQ to look at the impact of bolus timing on fat/protein.

• Age: 13-18
• Contact: rebecca.wesch@ucsf.edu

Trial Net screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D,  between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.

• Location: In home kit or lab test kit
• Age: 2.5-45
• Contact: David Kim at david.kim@joslin.harvard.edu or 888-813-8669

Autoimmunity Screening for Kids (ASK) A research program offering SCREENINGS AT NO COST to ALL U.S. children (ages 1-17) and adults to detect Type 1 Diabetes and Celiac.

• Age: 1+
• Contact: Questions@ASKhealth.org

The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants can sign up for other studies on various topics related to type 1 diabetes.

• Age: any
• Contact Kelsie LaFerriere at klaferriere@t1dexchange.org or Carolina Leon at cleon@t1dexchange.org

NEWLY DIAGNOSED

The FABULINUS study (FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy) is recruiting participants ages 12-35 within 90 days of diagnosis with at least 1 T1D autoantibody. The study is evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.

• Age: 12-35
• Contact:  Diablo Clinical, Meaghan Saint (925) 930-7267 ext. 223, msaint@diabloclinical.com
• Contact:  UCSF, Rebecca Wesch 415-476-5984, Rebecca.Wesch@ucsf.edu

The POLARIS Study (A Study of GNTI-122 in Adults Recently Diagnosed with T1D) is recruiting participants ages 18 to 45 within 120 days of T1D diagnosis. This is a Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant’s own blood cells in adult participants with recently diagnosed T1D.

• Age: 18-45
• Contact:  UCSF, Rebecca Wesch 415-476-5984, Rebecca.Wesch@ucsf.edu

The COUR CNP-103 Study is recruiting participants ages 12 to 35 within 6 months (180 days) of T1D diagnosis. This study is a Phase 1b/2a First-in-Human clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-103.

• Age: 12-35
• Contacts: Diablo Clinical Research, Drew Jaffe at 925-930-7287 djaffe@diabloclinical.com, or Catherine Morimoto cmorimoto@diabloclinical.com

MANAGEMENT

SUGARNSALT (Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease) is recruiting participants ages 18-75 living with T1D for at least 8 years with eGFR between 20-60 and urine ACR of 200+. Sotagliflozin has been shown to prevent or delay end-stage kidney disease in people with type 2 diabetes. This trial is investigating how these drugs work for people with T1D and safety of these drugs in the T1D population.

• Age: 18-75
• Contact: Stanford University Medical Center, Lorena Pineda ljpineda@stanford.edu, or Tugce Akcan, MD, takcan@stanford.edu

RESOURCES

What Are Clinical Trials Video

Clinical Trials and You Video

Match To Clinical Trials in 60 Seconds

Breakthrough T1D and Clinical Trials

TOPPLE Study Participant

Updated: Feb 4, 2026

Learn more about clinical trials here: